Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.43 |
| ▸ | P4HB | P07237 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.40 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.39 |
| ▸ | MLYCD | O95822 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.37 |
| ▸ | RXRA | P19793 | 1/20 | 0.37 |
| ▸ | RXRB | P28702 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17891892 | 0.88 | PDE3B (0.44) | PDE3BPDE3AEPHX2MEN1KMT2A | |
| SCHEMBL6293963 | 0.82 | ALDH1A1 (0.46) | ACE2P4HBEPHX2MEN1KMT2A | |
| SCHEMBL7842202 | 0.82 | S1PR1 (0.48) | S1PR1 | |
| SCHEMBL27671697 | 0.81 | PTPN1 (0.41) | ACE2P4HBEPHX2SRD5A2SMN1; SMN2 | |
| SCHEMBL16121258 | 0.80 | ACE2 (0.53) | ACE2P4HBEPHX2SRD5A2SMN1; SMN2 | |
| SCHEMBL17831712 | 0.80 | MLYCD (0.45) | PDE3BPDE3AEPHX2MLYCD | |
| SCHEMBL19480865 | 0.78 | PDE3B (0.38) | PDE3BPDE3AEPHX2MEN1KMT2A | |
| SCHEMBL1697891 | 0.78 | EPHX2 (0.44) | ACE2P4HBEPHX2SRD5A2SMN1; SMN2 | |
| SCHEMBL9184815 | 0.78 | EPHX2 (0.41) | ACE2P4HBEPHX2SRD5A2SMN1; SMN2 | |
| SCHEMBL3944077 | 0.77 | ALDH1A1 (0.50) | ACE2EPHX2MEN1KMT2ASRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373932-A1 | DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2023-11-23 | — | — | US | disclosed |
| US-20230373932-A1 | DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2023-11-23 | — | — | US | disclosed |
| US-20230373932-A1 | DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2023-11-23 | — | — | US | disclosed |
| US-20210130300-A1 | DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2021-05-06 | — | — | US | disclosed |
| US-20210130300-A1 | DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2021-05-06 | — | — | US | disclosed |
| EP-3744713-A1 | DIYHYDROPYRIMIDINE-2-ONE COMPOUNDS AND MEDICINAL USES THEREOF | Japan Tobacco Inc. (JP) | 2020-12-02 | — | — | EP | disclosed |
| EP-3744713-A1 | DIYHYDROPYRIMIDINE-2-ONE COMPOUNDS AND MEDICINAL USES THEREOF | Japan Tobacco Inc. (JP) | 2020-12-02 | — | — | EP | disclosed |
| CN-107001286-B | Dihydropyrimidine-2-one compounds and medicinal use thereof | 日本烟草产业株式会社 | 2020-07-07 | — | — | CN | disclosed |
| EP-3231793-B1 | DIHYDROPYRIMIDINE-2-ONE COMPOUNDS AND MEDICINAL USES THEREOF | JAPAN TOBACCO INC (JP) | 2020-03-11 | — | — | EP | disclosed |
| US-10196363-B2 | Dihydropyrimidin-2-one compounds and medical use thereof | JAPAN TOBACCO INC. (JP) | 2019-02-05 | — | — | US | disclosed |
| US-10196363-B2 | Dihydropyrimidin-2-one compounds and medical use thereof | JAPAN TOBACCO INC. (JP) | 2019-02-05 | — | — | US | disclosed |
| EP-3231793-A1 | DIHYDROPYRIMIDINE-2-ONE COMPOUNDS AND MEDICINAL USES THEREOF | JAPAN TOBACCO INC. (JP) | 2017-10-18 | — | — | EP | disclosed |
| EP-3231793-A1 | DIHYDROPYRIMIDINE-2-ONE COMPOUNDS AND MEDICINAL USES THEREOF | JAPAN TOBACCO INC. (JP) | 2017-10-18 | — | — | EP | disclosed |
| CN-107001286-A | The assimilation compound of dihydro-pyrimidin 2 and its medical usage | 日本烟草产业株式会社 | 2017-08-01 | — | — | CN | disclosed |
| US-20160194290-A1 | DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2016-07-07 | — | — | US | disclosed |
| US-20160194290-A1 | DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2016-07-07 | — | — | US | disclosed |
| US-20160194290-A1 | DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2016-07-07 | — | — | US | disclosed |
| WO-2016093342-A1 | DIHYDROPYRIMIDINE-2-ONE COMPOUNDS AND MEDICINAL USES THEREOF | 日本たばこ産業株式会社 | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10196363-B2 | Dihydropyrimidin-2-one compounds and medical use thereof | REN, PKD2, ALPI | PDE3B 875/4885PDE3A 740/4885ACE2 25/4885 |
| US-20160194290-A1 | DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF | REN, PKD2, ALPI | PDE3B 875/4885PDE3A 740/4885ACE2 25/4885 |
| US-20210130300-A1 | DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF | REN, PKD2, ALPI | PDE3B 875/4885PDE3A 740/4885ACE2 25/4885 |
| US-20230373932-A1 | DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF | REN, PKD2, ALPI | PDE3B 875/4885PDE3A 740/4885ACE2 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.